Hematologic Oncology Update
Dr. Neil Love
Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.
Episodes
Mentioned books
Jan 21, 2026 • 1h 1min
Bispecific Antibodies in the Management of Lymphoma — ASH 2025 Review
Prof Michael Dickinson from Peter MacCallum Cancer Centre in Melbourne, Australia, and Dr Laurie H Sehn from the University of British Columbia in Vancouver, Canada, discuss clinical cases and recent findings from the 2025 ASH Annual Meeting relating to the use of bispecific antibodies in the management of lymphoma.CME information and select publications here.
Jan 16, 2026 • 1h 1min
Relapsed/Refractory Multiple Myeloma — ASH 2025 Review
Dr Sagar Lonial from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr María-Victoria Mateos from the University Hospital of Salamanca in Salamanca, Spain, discuss cases of relapsed/refractory multiple myeloma and recentresearch findings from the 2025 ASH Annual Meeting. CME information and select publications here.
Jan 13, 2026 • 1h 57min
Follicular Lymphoma and Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition
Dr Nancy L Bartlett from the Washington University School of Medicine, Dr John P Leonard from the Perlmutter Cancer Center, Dr Matthew Matasar from Rutgers Cancer Institute, Dr Loretta J Nastoupil from Southwest Oncology and Prof Pier Luigi Zinzani from the University of Bologna in Italy discuss recent updates on available and novel treatment strategies for follicular lymphoma and diffuse large B-cell lymphoma. CME information and select publications here.
Jan 9, 2026 • 1h 58min
Myelofibrosis and Systemic Mastocytosis — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition
Prof Claire Harrison from Guy’s and St Thomas’ NHS Foundation Trust in London, Dr Andrew T Kuykendall from Moffitt Cancer Center, Dr Stephen T Oh from the Washington University School of Medicine, Dr Jeanne Palmer from the Mayo Clinic School of Medicine and Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center discuss recent updates on available and novel treatment strategies for myelofibrosis and systemic mastocytosis.CME information and select publications here.
Jan 7, 2026 • 1h 56min
Chronic Lymphocytic Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition
Dr Matthew S Davids from Dana-Farber Cancer Institute, Dr Bita Fakhri from Stanford University School of Medicine, Prof Constantine Tam from Alfred Health in Melbourne, Australia, and Dr Jennifer Woyach from The Ohio State University Comprehensive Cancer Center review the treatment landscape for patients with chronic lymphocytic leukemia and discuss current research immediately before the 67th ASH Annual Meeting.CME information and select publications here.
Jan 3, 2026 • 1h 58min
Acute Myeloid Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition
Dr Harry Paul Erba from the Duke Cancer Institute, Dr Amir Fathi from Massachusetts General Hospital, Dr Tara L Lin from The University of Kansas Medical Center, Dr Alexander Perl from the University of Pennsylvania’s Abramson Cancer Center and Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center discuss recent data surrounding the management of AML and their perspectives on clinical application.CME information and select publications here.
Dec 12, 2025 • 51min
Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology Network
Dr. Kerry A. Rogers is an Associate Professor in the Division of Hematology at The Ohio State University, where she specializes in chronic lymphocytic leukemia (CLL). In the discussion, she outlines the latest treatment options, comparing continuous BTK inhibitors with venetoclax-based therapies. Dr. Rogers shares insights on emerging agents, including sonrotoclax and pirtobrutinib, and emphasizes the importance of MRD testing. She also presents case studies that highlight personalized treatment strategies depending on patient profiles and comorbidities.
Dec 11, 2025 • 59min
CAR T-Cell Therapy for Non-Hodgkin Lymphoma | Cancer Q&A — Discussing Common Questions Posed by Patients
In this insightful discussion, Dr. Jeremy S Abramson, a lymphoma specialist at Massachusetts General Hospital, and Dr. Loretta J Nastoupil from CommonSpirit Mercy Hospital explore the landscape of CAR T-cell therapy for non-Hodgkin lymphoma. They delve into patient access challenges, revealing under 20% of eligible patients reach treatment centers. The pair compare CAR T products and emphasize the importance of logistical support for patients. They also address the significance of wellness strategies and community collaboration in enhancing patient care.
Dec 4, 2025 • 52min
Toxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew Lunning
Dr. Matthew Lunning, a hematologist-oncologist from the Fred and Pamela Buffett Cancer Center, shares vital insights on managing CAR T-cell therapy toxicities. He discusses the evolution of CRS and ICANS management and highlights the importance of long-term studies and referral timing. Lunning compares CAR T products, emphasizing the advantages of lisocabtagene for older patients. He also shares intriguing case studies that reveal the nuances of treatment outcomes, particularly in managing neurotoxic effects and patient quality of life.
Nov 15, 2025 • 60min
Patient Education Resource: Non-Hodgkin Lymphoma — Clinical Experts Address Common Questions Posed by Patients About CAR T-Cell Therapy
Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Manali Kamdar from the University of Colorado Cancer Center in Aurora discuss patient questions and experiences with CAR T-cell therapy for non-Hodgkin lymphoma. Educational information and select publications here.
